Interestingly, we observed in both cases that cotransfer of 14 days polyclonally expanded CD8+CD45RClow/− Tregs significantly inhibited skin graft rejection (Figure 5A), as well as GVHD (Figure 5B) and for both in a dose-dependent manner at 1:2 and 1:4 ratios, demonstrating the potential of the CD8+CD45RClow/− Tregs as a cell therapy. Here, CD8A is linked to graft versus host disease.